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Oral bisphosphonates and 
colorectal cancer
Emily Vogtmann1, Douglas A. Corley2, Lucy M. Almers2, Chris R. Cardwell3, Liam J. Murray3 & 
Christian C. Abnet1
Use of oral bisphosphonates has been associated with a decreased risk of colorectal cancer (CRC), but 
the association may be related to residual confounding by healthy lifestyle or body mass index (BMI). 
Therefore, we conducted a prospective nested case-control study within the Kaiser Permanente, 
Northern California health system cohort. In total, 12,505 CRC cases were individually matched to 
599,534 controls. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional 
logistic regression models with adjustment for important covariates extracted from the database. 
Participants who had ever used oral bisphosphonates were less likely than non-users to be diagnosed 
with CRC (OR 0.82; 95% CI: 0.74, 0.89). Colon and rectum site-specific associations were similar to 
the overall association. A stronger inverse association for ever use of bisphosphonates was observed 
for men (OR 0.63; 95% CI: 0.47, 0.85), however when stratified by previous lower endoscopy, the 
association was only observed in the participants who did not have a previous lower endoscopy 
(OR 0.73 (0.64, 0.83)). In conclusion, we found that oral bisphosphonate use was associated with a 
decreased odds of CRC, however this association may be due to residual confounding by BMI or another 
confounder.
Osteoporosis is a highly prevalent condition within the aging population of the United States, where it is estimated 
that 10.3% of the population aged 50 and older have osteoporosis1. Bisphosphonates are widely prescribed drugs 
used for the treatment of osteoporosis, so exposure to bisphosphonates is common among older adults. There is 
some evidence that bisphosphonates, in addition to inhibiting bone resorption, may also have anti-tumorigenic 
effects through several proposed mechanisms2. One proposed mechanism is through human epidermal growth 
factor receptors (HER) where nitrogen containing bisphosphates appear to kill specific cancer cell lines, including 
colon cancer cell lines, which either have activating mutations or overexpression of HER13.
Some previous studies have considered the association between oral bisphosphonate use and the risk of 
colorectal cancer4–13. These studies generally found an inverse association (i.e., a decreased risk of colorectal 
cancer with use of oral bisphosphonates)4–6,9,10 or no significant association7,8,11–13. With the exception of the ear-
liest meta-analysis14, the resulting meta-analyses have concluded that oral bisphosphonates are associated with 
a decreased risk of colorectal cancer15–19. However, a recent review of observational studies and meta-analyses 
considering the association of oral bisphosphonates and colorectal cancer suggested that residual confounding 
may explain the detected inverse associations20. Additionally, only a few studies5,6,10 considered site-specific asso-
ciations. Colon and rectal cancer do not share all of the same risk factors and therefore, the association may be 
different by site. To address these issues, we conducted a nested case-control study considering how oral bis-
phosphonate use was associated with the risk of colon and rectal cancer using data from the Kaiser Permanente, 
Northern California (KPNC) health system.
Results
From 1997 to 2011 in KPNC there were 12,505 colorectal cancer cases which were matched by sex, age at time 
of index date (+ /−2 years), duration of membership prior to the index date (+ /−1 year), race, and region of 
residence to 599,534 controls. Membership duration prior to the index date ranged from a minimum of 2 years 
to a maximum of 15.4 years with an interquartile range of 4.6 to 11 years. A total of 563 colorectal cancer cases 
(4.50%) had ever used oral bisphosphonates at least one year prior to the index date compared to 32,897 (5.49%) 
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of the controls. The colorectal cancer cases had a higher proportion of smokers (40.09%) compared to the controls 
(35.84%) and a higher proportion of alcohol consumers (24.77% versus 21.94%) (Table 1).
Overall, participants who had ever used bisphosphonates at least one year prior to the index date were less 
likely to develop colorectal cancer than non-users (odds ratio (OR) 0.77; 95% confidence interval (CI): 0.71, 
0.85) in unadjusted conditional logistic regression models. After adjustment for age, smoking, alcohol use, the 
Charlson comorbidity index (CCI), use of non-steroidal anti-inflammatory drugs (NSAIDS), and previous lower 
endoscopy, the OR was slightly attenuated (OR 0.82; 95% CI: 0.74, 0.89). The OR were general similar for shorter 
(< 12 months) and longer duration (≥ 12 months) of oral bisphosphonate use as measured using the Defined 
Daily Dose (DDD) (Table 2). When previous lower endoscopy was excluded from adjustment, the OR estimates 
were similar to the unadjusted models (Supplemental Table 1).
Oral bisphosphonate use was associated with a decreased odds of colorectal cancer for most cancer sites. For 
example, the ORs for cancer of the cecum, ascending colon, sigmoid colon, and rectum were 0.86 (95% CI: 0.72, 
1.03), 0.79 (95% CI: 0.63, 0.99), 0.77 (95% CI: 0.61, 0.96), and 0.73 (95% CI: 0.56, 0.94) respectively (Table 3). 
Among the 51.32% of participants with body mass index (BMI) data, inclusion of BMI slightly attenuated the 
association between ever use of bisphosphonates and colorectal cancer from an OR of 0.89 (95% CI: 0.80, 0.99) 
to an OR of 0.92 (95% CI: 0.83, 1.02) (Table 4). Stratified models within normal weight, overweight, and obese 
individuals provided generally similar association estimates between bisphosphonates and colorectal cancer 
(Supplemental Table 2). Since participants who had measured BMI data in this cohort tended to have been a 
member of KPNC for more years (mean 10.2 years) compared to those without BMI data (mean 5.4 years), we 
stratified the sample by membership duration, less than or equal to the first quartile of membership duration 
(≤ 4.6 years) and the top three quartiles (> 4.6 years). A stronger association was detected among participants 
Cases Controls
N/Mean %/SD N/Mean %/SD
Number of participants 12,505 599,534
Ever oral bisphosphonates (> 1 yr) 563 4.50% 32,897 5.49%
Ever use oral alendronate (> 1 yr) 556 4.45% 32,281 5.38%
Ever use oral etidronate (> 1 yr) 13 0.10% 785 0.13%
Ever use oral ibandronate (> 1 yr) 4 0.03% 206 0.03%
Ever use oral risedronate (> 1 yr) 14 0.11% 989 0.16%
Ever use oral tiludronate (> 1 yr) 0 0.00% 4 0.00%
Defined Daily Dose
 Never 11,942 95.50% 566,637 94.51%
 < 12 months 224 1.79% 11,928 1.99%
 > = 12 months 339 2.71% 20,969 3.50%
Age at index 66.40 13.00 65.94 12.90
Female 6,027 48.20% 290,996 48.54%
Race/ethnicity
 Non-Hispanic white 7,519 60.13% 373,257 62.26%
 Non-Hispanic black 1,139 9.11% 51,400 8.57%
 Hispanic 1,629 13.03% 75,522 12.60%
 Other 2,162 17.29% 97,087 16.19%
 Missing 56 0.45% 2,268 0.38%
Smoked tobacco (% yes) 5,013 40.09% 214,862 35.84%
Consumed alcohol (% yes) 3,097 24.77% 131,538 21.94%
Body mass index
 Missing 6,286 50.27% 291,630 48.64%
 Underweight 17 0.14% 665 0.11%
 Normal weight 2,038 16.30% 108,945 18.17%
 Overweight 1,859 14.87% 96,253 16.05%
 Obese 2,305 18.43% 102,041 17.02%
Charlson comorbidity index 0.85 1.97 0.18 0.79
History of osteoporosis (> 1 yr) 5,986 47.87% 308,108 51.39%
Previous lower endoscopy 6,492 51.92% 271,688 45.32%
Previous lower endoscopy (> 1 yr) 3,492 27.92% 248,160 41.39%
Previous upper endoscopy (> 1 yr) 525 4.20% 37,182 6.20%
Ever use HRT (> 1 yr) 2,602 20.81% 146,633 24.46%
Ever use NSAIDs (> 1 yr) 8,264 66.09% 427,351 71.28%
Table 1.  Descriptive characteristics of colorectal cancer cases and controls, Kaiser Permanente, Northern 
California, 1997–2011. Note: >1 yr indicates that the exposure occurred at least one year prior to the index date.
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with a short membership duration with an OR for ever use of oral bisphosphonates of 0.66 (95% CI: 0.48, 0.91), 
but the association within participants with a longer duration of membership was similar to the original model 
(Supplemental Table 1).
A stronger inverse association for ever use of bisphosphonates was observed for men (OR 0.63; 95% CI: 0.47, 
0.85), although the interaction between sex and oral bisphosphonates on colorectal cancer was only statistically 
significant for the ever use of oral bisphosphonates (p = 0.0426) (Table 5). When we included adjustment for BMI 
in the stratified analysis, the estimates were only slightly attenuated compared to the model within the population 
with BMI measured (Supplemental Table 3). In the models for women, adjustment for hormone replacement 
therapy (HRT) use did not change the estimates (Supplemental Table 1).
Unadjusted Adjusted
OR (95% CI) OR (95% CI)
Ever use oral bisphosphonates 0.77 (0.71, 0.85) 0.82 (0.74, 0.89)
Defined Daily Dose
 Never Ref Ref
 < 12 months 0.85 (0.74, 0.98) 0.83 (0.72, 0.96)
 > = 12 months 0.73 (0.65, 0.82) 0.81 (0.72, 0.90)
Table 2.  Association between oral bisphosphonate use and colorectal cancer, Kaiser Permanente, Northern 
California, 1997–2011. Cases and controls were matched on sex, age at time of index date (+ /−2 years), 
duration of membership prior to index date (+ /−1 year), race, and region of residence. The adjusted model 
additionally included age, smoking, alcohol use, Charlson comorbidity index, use of NSAIDs, and previous 
lower endoscopy.
N cases OR (95% CI)
Site-specific associations
Cecum 2,195 0.86 (0.72, 1.03)
Appendix 131 0.19 (0.03, 1.42)
Ascending colon 1,648 0.79 (0.63, 0.99)
Hepatic flexure of colon 541 0.84 (0.57, 1.26)
Transverse colon 830 1.15 (0.86, 1.54)
Splenic flexure of colon 348 0.63 (0.33, 1.21)
Descending colon 547 1.01 (0.64, 1.60)
Sigmoid colon 2,803 0.77 (0.61, 0.96)
Overlapping lesion of colon 61 0.55 (0.15, 2.10)
Colon, NOS 149 0.40 (0.14, 1.15)
Rectosigmoid junction 752 0.66 (0.42, 1.02)
Rectum 2,500 0.73 (0.56, 0.94)
Table 3.  Association between oral bisphosphonate use and colorectal cancer sites, Kaiser Permanente, 
Northern California, 1997–2011. Cases and controls were matched on sex, age at time of index date  
(+ /− 2 years), duration of membership prior to index date (+ /− 1 year), race, and region of residence. The 
adjusted model additionally included age, smoking, alcohol use, Charlson comorbidity index, use of NSAIDs, 
and previous lower endoscopy.
OR without adjustment 
for BMI (95% CI)
OR with adjustment 
for BMI (95% CI)
Ever use oral 
bisphosphonates 0.89 (0.80, 0.99) 0.92 (0.83, 1.02)
Defined Daily Dose
 Never Ref Ref
 < 12 months 0.93 (0.79, 1.09) 0.95 (0.81, 1.12)
 > = 12 months 0.87 (0.76, 0.99) 0.90 (0.79, 1.02)
Table 4.  Association between oral bisphosphonate use and colorectal cancer after adjustment for body 
mass index among participants with measured body mass index, Kaiser Permanente, Northern California, 
1997–2011. Cases and controls were matched on sex, age at time of index date (+ /−2 years), duration of 
membership prior to index date (+ /−1 year), race, and region of residence. The adjusted model additionally 
included age, smoking, alcohol use, Charlson comorbidity index, use of NSAIDs, and previous lower endoscopy.
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When the data were stratified by having a previous lower endoscopy at least one year prior to the index date, 
the inverse association between ever use of oral bisphosphonates was only observed in the participants who did 
not have a previous lower endoscopy at least one year prior to the index date (OR 0.73; 95% CI: 0.64, 0.83), while 
no association (OR 0.92; 95% CI: 0.80, 1.04) was observed among those that had a previous lower endoscopy 
(Table 6).
Discussion
In this study of 12,505 colorectal cancer cases and 599,534 controls from KPNC, we found that bisphosphonate 
use was associated with a decreased odds of colorectal cancer particularly among participants without prior 
endoscopic colorectal cancer screening procedures. In general, bisphosphonates decreased the odds of cancer in 
colon and rectum site-specific analyses. There was some evidence for residual confounding by BMI, although the 
association between bisphosphates and colorectal cancer was overall weaker within participants who had BMI 
measured compared to the whole study population. The association between bisphosphonate use and colorectal 
cancer was stronger within males compared to females and the association was restricted to participants who did 
not have a previous lower endoscopy at least one year prior to the index date.
Our overall finding of a decreased odds of colorectal cancer for participants who used oral bisphosphonate is 
in agreement with a number of previous studies4–6,9,10 and the majority of previous meta-analyses15–19. In a previ-
ous study which evaluated the association by site also found inverse associations between oral bisphosphonate use 
and cancer of the right colon (OR 0.49; 95% CI: 0.29, 0.85), left colon (OR 0.50; 95% CI: 0.29, 0.86), and rectum 
(OR 0.50; 95% CI: 0.23, 1.08)5. Another study found a stronger inverse association between bisphosphonates and 
OR (95% CI)
Ever use oral bisphosphonates
 Females 0.84 (0.76, 0.92)
 Males 0.63 (0.47, 0.85)
 p interaction 0.0426
Defined Daily Dose
 Females
  Never Ref
  < 12 months 0.84 (0.73, 0.98)
  > = 12 months 0.83 (0.74, 0.94)
 Males
  Never Ref
  < 12 months 0.71 (0.47, 1.08)
  > = 12 months 0.56 (0.36, 0.86)
 p interaction (<12) 0.3194
 p interaction (> = 12) 0.0596
Table 5.  Sex-specific associations between oral bisphosphonates and colorectal cancer, Kaiser Permanente, 
Northern California, 1997–2011. Cases and controls were matched on sex, age at time of index date (+ /−2 
years), duration of membership prior to index date (+ /−1 year), race, and region of residence. The adjusted 
model additionally included age, smoking, alcohol use, Charlson comorbidity index, use of NSAIDs, and 
previous lower endoscopy.
OR (95% CI)
Previous lower endoscopy
Ever use oral bisphosphonates 0.92 (0.80, 1.04)
Defined Daily Dose
 Never Ref
 < 12 months 0.93 (0.76, 1.15)
 > = 12 months 0.91 (0.77, 1.06)
No previous lower endoscopy
Ever use oral bisphosphonates 0.73 (0.64, 0.83)
Defined Daily Dose
 Never Ref
 < 12 months 0.76 (0.63, 0.91)
 > = 12 months 0.71 (0.60, 0.83)
Table 6.  Associations between oral bisphosphonates and colorectal cancer stratified by previous lower 
endoscopy at least one year prior to the index date, Kaiser Permanente, Northern California, 1997–2011. 
The unconditional logistic regression model adjusted for age, sex, race, region, years of KPNC membership, 
smoking, alcohol use, Charlson comorbidity index, and use of NSAIDs.
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cancer of the distal colon6 while a third study found a decreased risk for cancers of the colon and rectum, but not 
for cancers of the rectosigmoid junction10.
Of the studies which adjusted for BMI, three studies found an inverse or marginally inverse association4,5,9, 
while three other studies found no statistically significant association11,13 or a marginally weak increased risk7 of 
colorectal cancer after use of oral bisphosphonates. Three of these studies included overlapping populations from 
the Clinical Practice Research Datalink (CPRD; previously known as the General Practice Research Database)4,7,9, 
and the most recent study7 had the lowest percentage of missing BMI data and found a weakly positive association 
(OR 1.10; 95% CI: 1.00, 1.22) between bisphosphonate use and colorectal cancer specifically within the CPRD7. 
This suggests that the inverse association may be due to residual confounding by BMI20. We similarly found no 
significant association between oral bisphosphonates and colorectal cancer after adjustment for BMI, although 
a large proportion of participants were missing BMI data and the association between oral bisphosphonates and 
colorectal cancer was weaker within the population that had BMI data. This weaker association may be related 
to membership duration since participants with measured BMI tended to be members of KPNC for a longer 
duration, but when participants with a short duration of membership were excluded, the association between 
bisphosphonates and colorectal cancer was unchanged from the initial estimate. In addition, participants with a 
longer membership duration would have more accurate measures of bisphosphonate exposure compared to those 
with a shorter duration of membership.
Many previous studies were conducted only among women5,10–13. Of these, only two studies5,10 detected a 
decreased risk of colorectal cancer among women who used oral bisphosphonates. We detected a statistically 
significant inverse association between oral bisphosphonates and colorectal cancer among women, however a 
stronger inverse association was detected for men. In a nested case-control study within the Manitoba Health 
administrative database, a stronger, albeit not statistically significant association with colorectal cancer was 
detected within men (OR 0.56; 95% CI: 0.28, 1.11) compared to women (OR 0.81; 95% CI: 0.67, 0.98) for having 
14 or more versus 0–1 bisphosphonate prescriptions6 which was very similar to our estimates for men (OR 0.56; 
95% CI: 0.36, 0.86) and women (OR 0.83; 95% CI: 0.74, 0.94) for a defined daily dose of a year or more of oral 
bisphosphonates. However, in one of the CPRD studies, the association estimates were similar for men (hazard 
ratio [HR] 0.78; 95% CI: 0.47, 1.28) and women (HR 0.74; 95% CI: 0.56, 0.97)9. It has been suggested that bisphos-
phonate users may be a more health conscious group20, which may be particularly pronounced among men and 
may explain our stronger findings.
Few previous studies evaluated effect modification by previous lower endoscopy11,13. In one of these studies, 
no associations were detected between oral bisphosphonate use and colorectal cancer in both the group with 
a previous lower endoscopy (HR 1.08; 95% CI: 0.75, 1.54) and the group without a previous lower endoscopy 
(HR 1.03; 95% CI: 0.74, 1.43)11. In our data, the inverse association between oral bisphosphonates and colorectal 
cancer appeared to be restricted to participants who had not had a lower endoscopy at least one year prior to the 
index date. Another previous study found an association between oral bisphosphonates and colorectal cancer 
overall, but when the analyses were restricted to advanced stage colorectal cancer, no statistically significant asso-
ciation was detected6. This may suggest that oral bisphosphonates may only prevent slow growing or early stage 
cancers, which would not be detected when regular lower endoscopies are used since these slow growing cancers 
would be removed in a lower endoscopy. However, we were unable to consider cancer stage and therefore this 
hypothesis should be tested in an independent population with additional data. The effect of oral bisphosphonates 
may also be similar to that of aspirin on colorectal cancer risk. In a cost-effectiveness analysis of aspirin, it was 
found that the use of aspirin for chemoprevention would only be beneficial in a population without colorectal 
cancer screening since colorectal cancer screening is highly cost-effective and greatly reduces the risk of colorectal 
cancer21.
This study has some limitations. All of the data for this study were obtained from claims data which may not 
completely represent the participants’ exposure history. For example, BMI data were missing for almost half of 
the participants, so the analyses which adjusted for BMI were restricted to participants with recorded BMI data. 
In addition, we were unable to adjust for a number of other potential confounders such as supplemental calcium 
and vitamin D since these are commonly prescribed over the counter and therefore would not be included in 
claims data, although a recent trial found no utility of a combination of aspirin, calcitriol, and calcium carbonate 
to prevent colorectal adenoma recurrence22. We only had limited information about lower endoscopy, so we were 
unable to investigate whether these lower endoscopies found and removed polyps. This study also was conducted 
in an insured population, so our findings may not be representative of individuals without insurance or without 
comprehensive coverage. However, a previous study suggests that the KPNC population is fairly representative 
of the region of coverage23. Finally, we did not have information on cancer stage at diagnosis, so future studies 
should further consider the association between oral bisphosphonates and colorectal cancer stage.
There are also a number of strengths. Our study included a very large number of colorectal cancer cases 
and controls from a comprehensive insurance system in the United States, with comprehensive capture of phar-
macy exposure data and cancer outcomes. Due to this large sample size, we were also able to look at detailed 
site-specific association. Since enrollees of KPNC receive almost all of their health care through KPNC, it is 
unlikely that there are significant missing utilization or prescription data. The cancer registry of KPNC captures 
over 98% of cancer diagnoses and all colorectal cancer cases were identified through this registry.
In conclusion, we found an inverse association between oral bisphosphonate use and colorectal cancer within 
participants who had not had a previous lower endoscopy, however this association may be due to residual con-
founding by BMI, healthy lifestyle, or another unmeasured confounder. It is unlikely that oral bisphosphonates 
should be used to decrease colorectal cancer risk at the population level.
www.nature.com/scientificreports/
6Scientific RepoRts | 7:44177 | DOI: 10.1038/srep44177
Methods
Source population. For this study, we used similar methods to a previously published study of oral bisphos-
phonates and upper gastrointestinal cancer in KPNC24. We selected cases and controls from adults (≥ 18 years 
old) who were members of the KPNC health system from 1997 to 2011. Kaiser Permanente is the largest not for 
profit health plan in California with membership around 3.3 million members in northern California who have 
been found to be generally representative of the residents of that region23. The KPNC Institutional Review Board 
approved this study and the requirement of written informed consent was waived. All methods were performed 
in accordance with relevant guidelines and regulations.
Case ascertainment. Cases of invasive colorectal cancer (ICD-10: C18, C19, and C20) were selected from 
the KPNC cancer registry and the index date was considered the date of the diagnosis. To be included, cases had 
to be at least 18 years old at the colorectal cancer diagnosis and have at least 2 years of membership in KPNC 
prior to diagnosis. If a case had a history of cancer prior to colorectal cancer (identified using the cancer registry 
or ICD-9 V codes) or a history of Paget’s disease (ICD-9: 731.0) that case was excluded. We identified 12,505 
colorectal cancer cases in total. We assigned the specific site within the colon and rectum based on the ICD-O-3 
codes.
Control selection. We identified up to 50 controls in the KPNC database which were matched without 
replacement to the cases based on sex, age at the index date (+ /−2 years), membership duration before the index 
date (+ /−1 year), race, and residential region. To be included, controls had to be at least 18 years of age, a KPNC 
member at the time of the index date for the matched case, and been a KPNC member for at least two years before 
the matched case’s index date. We identified 599,534 controls for this study.
Assessment of oral bisphosphonate exposure. We collected data on prescription fills of oral bisphos-
phonate, including alendronate, etidronate, ibandronate, risedronate, and tiludronate, for the time before the 
index date for both cases and controls. The exposure to oral bisphosphonates was categorized as ever exposed 
(at least one prescription fill one year of more before the index date) or never exposed. For the participants who 
were ever exposed to oral bisphosphonates, the defined daily dose (DDD) of bisphosphonate exposure was calcu-
lated for data collected before the index date. We dichotomized the DDD variable as less than 12 months exposed 
or 12 or more months exposed25.
Other covariates of interest. Other covariates before the index date were utilized for analysis. We included 
age, sex, race/ethnicity, history of smoking and alcohol consumption, BMI, the CCI26, a diagnosis of osteoporosis 
at least one before the index date, a prescription drug fill for HRT or NSAIDs at least one before the index date, 
and a history of an upper or lower endoscopy at least one year before the index date. The BMI variable was based 
on the mode of the height and the median weight for all measured heights and weights prior to the year leading 
up to the index date. BMI was missing for a large proportion of participants (48.68% missing), so we used the BMI 
data primarily in sensitivity analyses.
Statistical analysis. We calculated descriptive statistics for the colorectal cancer cases and controls for the 
covariates of interest. We then created conditional logistic regression models for the association of ever use of 
bisphosphonates and DDD with colorectal cancer27. Models with adjustment for potential confounders, including 
age, smoking status, alcohol use, CCI, use of NSAIDs, and a previous lower endoscopy were also created. A con-
ditional logistic regression model for each ICD-O-3 site was created with adjustment for potential confounders.
We additionally conducted several sensitivity analyses. We created a conditional logistic regression model 
which excluded adjustment for previous lower endoscopy. A conditional logistic regression model for only partic-
ipants with a valid BMI was created and then we separately tested the inclusion of BMI in adjustment. We created 
a stratified model by duration of membership prior to the index date. The short duration of membership was the 
first quartile of membership duration (≤ 4.6 years) and the long duration of membership was the top three quar-
tiles of membership duration (> 4.6 years). Sex-stratified conditional logistic regression models were created and 
we additionally tested the inclusion of adjustment for hormone replacement therapy in the model for females. 
We created unconditional logistic regression models stratified by previous lower endoscopy and by BMI category. 
In order to keep all cases and controls in the analysis, we broke the matched pairs and included all mentioned 
potential confounders and additionally adjusted for the matching covariates including sex, race, region, and years 
of KPNC membership. We conducted the statistical analyses using SAS 9.3.
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